HMN 2025: How Alzheimer’s disease medication shows promise for improving social impairment in some youth with autism

Some people with autism spectrum disorder (ASD) have abnormal levels of glutamate in the brain. New research led by Mass General Brigham has focused on this neuron-activating chemical, suggesting that a glutamate-modulating drug called memantine may improve social functioning in youth with ASD who do not have intellectual disabilities.

The randomized clinical trial of 42 participants also found that participants with elevated glutamate in a specific brain region responded more favorably to treatment, which could help identify individuals most likely to benefit from treatment.

Results are published in JAMA Network Open.

“If you have elevated blood glucose, we prescribe antidiabetic medications to decrease blood sugar levels. In the same way, we looked to see if glutamate modulators could improve social functioning in autism for individuals with abnormally high brain glutamate levels,” said corresponding author Gagan Joshi, MD, director of the Bressler Program for Autism Spectrum Disorder at Massachusetts General Hospital. “We saw that patients who responded to memantine became more socially engaged.”

ASD affects more than 2% of all children and is characterized by difficulties in social interactions and communication. Prior research evaluating the effects of glutamate-modulating treatments on symptoms of autism have reported mixed results. These studies include memantine, a drug currently approved for treating moderate to severe Alzheimer’s disease.

The researchers hypothesized that negative findings could be due to the use of lower drug doses and the inclusion of a broader range of participants with intellectual difficulties. A preliminary study that employed optimal doses of memantine in adults with ASD had demonstrated promising results.

In this study, researchers built on these results. The team performed a 12-week, randomized, controlled trial involving ASD participants without intellectual disability between the ages of 8 and 18. Of the cohort of 42 participants, 33 completed the trial, with 16 participants receiving memantine and 17 receiving placebo. In addition, 37 of the participants with ASD, as well as an additional 16 healthy controls, underwent scanning to evaluate the pregenual anterior cingulate cortex (pgACC), a glutamate-rich brain region responsible for social processing and emotional awareness.

Memantine treatment was associated with a significantly higher rate of improvement in social behaviors (56%) compared to placebo (21%) and was generally well tolerated, although some participants reported mild side effects such as headaches. Furthermore, participants with ASD had elevated glutamate levels in the pgACC when compared to healthy controls. Among individuals with ASD, 54% had high levels of pgACC glutamate, while the remaining 46% had medium levels.

The investigators determined that treatment response varied based on pgACC glutamate activity. All memantine responders had high glutamate levels, and 80% of participants with abnormally elevated glutamate levels responded favorably to memantine. These results suggest that pgACC glutamate measurement could serve as a biomarker to identify patients who will benefit from memantine treatment.

Further research is needed to establish whether high glutamate levels can predict treatment responses to other glutamate modulators.

“In our study, participants who responded to memantine showed improvements in social competence and a reduction in autism symptom severity, although they continued to experience milder features of autism,” said Joshi. “Larger clinical trials could help assess memantine responses in broader populations with ASD.”

The content is provided for information purposes only.